274 related articles for article (PubMed ID: 30634950)
1. Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review.
Abe M; Watanabe K; Shinozaki-Ushiku A; Ushiku T; Abe T; Fujihara Y; Amano Y; Zong L; Wang CP; Kubo E; Inaki R; Kinoshita N; Yamashita S; Takai D; Ushijima T; Nagase T; Hoshi K
BMC Cancer; 2019 Jan; 19(1):52. PubMed ID: 30634950
[TBL] [Abstract][Full Text] [Related]
2. PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience.
Mitiushkina NV; Kholmatov MM; Venina AR; Tiurin VI; Yanus GA; Sokolova TN; Yatsuk OS; Zaitseva OA; Ivantsov AO; Kuligina ES; Togo AV; Imyanitov EN
Neoplasma; 2018 Nov; 65(6):972-979. PubMed ID: 30334450
[TBL] [Abstract][Full Text] [Related]
3. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G
BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449
[TBL] [Abstract][Full Text] [Related]
4. Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.
DeMaio A; Clarke JM; Dash R; Sebastian S; Wahidi MM; Shofer SL; Cheng GZ; Li X; Wang X; Mahmood K
J Bronchology Interv Pulmonol; 2019 Apr; 26(2):96-101. PubMed ID: 30048416
[TBL] [Abstract][Full Text] [Related]
5. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
6. CDX-2 Expression in Primary Lung Adenocarcinoma.
Cowan ML; Li QK; Illei PB
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):16-9. PubMed ID: 26469326
[TBL] [Abstract][Full Text] [Related]
7. ALK immunohistochemistry is highly sensitive and specific for the detection of ALK translocated lung adenocarcinomas: lessons from an audit of lung cancer molecular testing.
Kheng YC; Walsh K; Williams L; Wallace WA; Harrison DJ; Oniscu A
J R Coll Physicians Edinb; 2018 Mar; 48(1):20-24. PubMed ID: 29741520
[TBL] [Abstract][Full Text] [Related]
8. Relationship of radiometabolic biomarkers to KRAS mutation status and ALK rearrangements in cases of lung adenocarcinoma.
Aras G; Kanmaz ZD; Tuncay E; Çetinkaya E; Yentürk E; Kocatürk C; Öz B; Çermik TF; Purisa S
Tumori; 2019 Dec; 105(6):501-508. PubMed ID: 31910789
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
[TBL] [Abstract][Full Text] [Related]
10. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W
Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865
[TBL] [Abstract][Full Text] [Related]
11. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
12. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis.
Takanashi Y; Tajima S; Hayakawa T; Neyatani H; Funai K
Int J Clin Exp Pathol; 2015; 8(11):15338-43. PubMed ID: 26823891
[TBL] [Abstract][Full Text] [Related]
14. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
[TBL] [Abstract][Full Text] [Related]
15. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
16. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
17. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
[TBL] [Abstract][Full Text] [Related]
18. Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report.
Fan J; Wu J; Huang B; Zhu Y; Shi H; Dai X; Nie X
Diagn Pathol; 2020 May; 15(1):42. PubMed ID: 32375829
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma.
Dhieb D; Belguith I; Capelli L; Chiadini E; Canale M; Bravaccini S; Yangui I; Boudawara O; Jlidi R; Boudawara T; Calistri D; Keskes LA; Ulivi P
Cells; 2019 May; 8(6):. PubMed ID: 31141932
[TBL] [Abstract][Full Text] [Related]
20. Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas.
Rossi G; Cavazza A; Righi L; Sartori G; Bisagni A; Longo L; Pelosi G; Papotti M
Int J Surg Pathol; 2014 Aug; 22(5):401-7. PubMed ID: 24651909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
